Loteprednol Etabonate Suspension Eye Drops (Lotemax) is a glucocorticoid ophthalmic preparation, mainly used for the treatment of ocular inflammatory diseases. As a topically applied corticosteroid, it can effectively reduce ocular inflammatory reactions, but at the same time, medication guidelines must be strictly followed to avoid potential adverse reactions.
Precautions for Using Loteprednol Etabonate Suspension Eye Drops (Lotemax)
Indications
Treatment of inflammation in the anterior segment tissues of the eye (such as palpebral conjunctiva, bulbar conjunctiva, and cornea) that are sensitive to corticosteroids.
Treatment and prevention of seasonal allergic conjunctivitis.
Control of post-cataract surgery inflammation.
Contraindications
Patients allergic to loteprednol or any component in the preparation.
Most viral infections of the cornea and conjunctiva (e.g., herpetic keratitis).
Ocular mycobacterial infections.
Ocular fungal infections.
Untreated purulent ocular infections.
Usage and Administration
Shake the suspension well before use.
Avoid contact between the tip of the dropper and any surface to prevent contamination.
After instilling the eye drops, gently press the lacrimal sac area for 2-3 minutes to reduce systemic absorption.
Combined medication: If other eye drops are used at the same time, an interval of at least 5 minutes is required.
Contact lenses: Avoid wearing soft contact lenses during the medication period.
Intraocular Pressure Elevation
The incidence is approximately 2-5%, mostly occurring 2-6 weeks after the start of medication.
Monitoring frequency: After the baseline examination, recheck the intraocular pressure 2-4 weeks after starting medication.
High-risk groups: Patients with glaucoma, diabetes, and high myopia.
Management measures: Reduce the dosage or discontinue the medication if there is a significant elevation of intraocular pressure.
Corneal Issues
Corneal thinning and perforation (especially in patients with a history of ocular herpes or eye surgery).
Secondary ocular infections (bacterial, fungal, or viral).
Delayed corneal wound healing.
Systemic Absorption
Children are more prone to systemic adverse reactions.
Long-term and high-dose use may inhibit the function of the hypothalamic-pituitary-adrenal (HPA) axis.
The lacrimal sac compression method is recommended to reduce systemic absorption.
Treatment Monitoring for Loteprednol Etabonate Suspension Eye Drops (Lotemax)
Intraocular Pressure Monitoring
Intraocular pressure measurement must be included in the baseline examination.
Recheck the intraocular pressure 2-4 weeks after starting medication.
For long-term users, monitor at least once every 2-3 months.
Visual acuity examination: Regularly assess changes in visual acuity.
Slit-lamp examination: Evaluate corneal integrity, anterior chamber reaction, etc.
Infection signs: Monitor for symptoms of potential secondary infections.
Special Monitoring Scenarios
Postoperative patients: Closely monitor the wound healing process.
Pediatric patients: Strengthen monitoring for systemic adverse reactions.
Long-term users: Regularly evaluate the function of the HPA axis.
Diabetic patients: More frequent intraocular pressure monitoring.
